Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer

Abstract Background Radium‐223 dichloride (Ra‐223) is a targeted alpha therapy that induces localized cytotoxicity in bone metastases. We evaluated the efficacy and safety of Ra‐223 plus hormonal therapy in hormone receptor‐positive (HR+), bone‐dominant metastatic breast cancer. Methods In this sing...

Full description

Bibliographic Details
Main Authors: Naoto T. Ueno, Rie K. Tahara, Takeo Fujii, James M. Reuben, Hui Gao, Babita Saigal, Anthony Lucci, Toshiaki Iwase, Nuhad K. Ibrahim, Senthil Damodaran, Yu Shen, Diane D. Liu, Gabriel N. Hortobagyi, Debu Tripathy, Bora Lim, Beth A. Chasen
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:Cancer Medicine
Subjects:
alphatherapy
bone metastasis
breast cancer
hormonal therapy
hormone receptor‐positive
Radium‐223 dichloride
Online Access:https://doi.org/10.1002/cam4.2780

Internet

https://doi.org/10.1002/cam4.2780

Similar Items